Related Experiment Videos
Long-term pharmacological prevention of heart failure after myocardial infarction
1Department of Medicine, University of California at San Diego, La Jolla.
Insights
Coronary artery disease (CAD) management is improving, but progressive heart damage persists. Early ACE-inhibitor treatment shows promise in limiting this damage and reducing heart failure after myocardial infarction.
Area of Science:
- Cardiology
- Cardiovascular Research
- Heart Failure Research
Background:
- Coronary artery disease (CAD) prevalence remains high despite decreasing mortality.
- Advanced treatments lead to a growing population with left ventricular damage.
- Post-ischemic damage progresses even without new ischemic events.
Purpose of the Study:
- To evaluate interventions for limiting progressive left ventricular damage post-ischemia.
- To assess the potential impact on heart failure prevalence and severity.
Main Methods:
- Review of clinical observations and experimental data on post-ischemic damage progression.
- Analysis of preliminary data on ACE-inhibiting drug administration post-myocardial infarction.
Main Results:
- Post-ischemic damage is progressive and can occur without recurrent ischemia.
- Early administration of ACE inhibitors shows encouraging preliminary results in limiting damage.
- Further multicenter trials are needed to confirm these findings.
Conclusions:
- Limiting progressive post-ischemic damage is crucial for managing heart failure.
- ACE inhibitors represent a potential therapeutic strategy for patients post-myocardial infarction.
- Clinical practice changes await results from ongoing large-scale trials.
Abstract:
The prevalence of coronary artery disease shows no signs that it is declining, yet mortality is decreasing and advanced methods of treatment are creating a large population of individuals with a substantially damaged left ventricle. Clinical observations and experimental data provide convincing evidence that postischemic damage is progressive even in the absence of a fresh ischemic insult. Any intervention capable of preventing or limiting this progression can reasonably be expected to make a strong favorable impact on the prevalence and severity of heart failure, defined as symptomatic ventricular dysfunction. Preliminary data indicating that this desirable result can be achieved by the administration of ACE-inhibiting drugs to patients soon after the onset of acute Q-wave myocardial infarction are encouraging, but recommendations for a major change in current clinical practice will have to await the results of major multicenter trials now in progress.